Merck’s TROP2 ADC opens global women’s cancer push with endometrial win

Merck’s TROP2 ADC, sacituzumab tirumotecan, delivered the week’s clearest late-stage win, meeting both overall survival and progression-free survival endpoints in advanced endometrial cancer, while Regenxbio and Regeneron lost ground after investors parsed late-stage readouts in Duchenne muscular dystrophy and melanoma.

Merck & Co. Inc. (NYSE:MRK) announced Monday that sacituzumab tirumotecan (sac-TMT) had become the first antibody-drug conjugate to improve survival in a global Phase III trial to treat advanced endometrial patients, an indication where ADCs against FRα and HER2 have yet to succeed...